10-Q: QT Imaging Reports Q2 2026 Results, Revenue Doubles

QT Imaging Holdings, Inc. announced its second quarter 2026 financial results, showcasing a significant increase in revenue driven by scanner sales, but also reporting substantial net losses and rising operating costs.

Summary

• QT Imaging Holdings, Inc. reported revenue of $7.4 million for the three months ended June 30, 2026, a 103% increase from $3.7 million in the same period last year, primarily due to selling more Breast Acoustic CT Scanners.
• The company incurred a net loss of $11.1 million for the quarter, compared to a $4.0 million loss in Q2 2025, with total operating expenses rising to $4.9 million from $2.9 million.
• For the six months ended June 30, 2026, revenue was $14.0 million, up 116% from $6.5 million in the prior year, while the net loss widened to $14.5 million from $15.1 million in the comparable period.
• Operating expenses for the six months increased to $9.9 million from $5.7 million, driven by higher research and development and selling, general, and administrative costs.
• The company ended the quarter with $10.9 million in cash and cash equivalents and continues to rely on capital raises to fund operations, with plans to raise additional capital as needed.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as cautiously negative due to significant net losses, increasing operating expenses, and ongoing reliance on capital raises, despite revenue growth and strategic distribution agreements.

Positives

• Revenue for the three months ended June 30, 2026, increased by 103% to $7.4 million, driven by the sale of 15 Breast Acoustic CT Scanners, up from 8 in the prior year's quarter.
• Revenue for the six months ended June 30, 2026, increased by 116% to $14.0 million, with 28 scanners sold compared to 14 in the prior year's period.
• The company secured regulatory approval from the Saudi Food and Drug Authority (SFDA) for its Breast Acoustic CT Scanner in Saudi Arabia on June 2, 2026.
• The company secured regulatory approval from the Emirates Drug Establishment (EDE) in the UAE for its Breast Acoustic CT Scanner on March 17, 2026.
• The company's common stock was uplisted to the Nasdaq Capital Market on January 28, 2026, trading under the symbol QTI.
• The maturity date of the Lynrock Lake Term Loan was extended to March 31, 2029, providing additional financial flexibility.

Negatives

• The company reported a net loss of $11.1 million for the three months ended June 30, 2026, a significant increase from a $4.0 million loss in the same period of 2025.
• For the six months ended June 30, 2026, the net loss was $14.5 million, compared to $15.1 million in the prior year, indicating continued operational losses.
• Total operating expenses for the three months ended June 30, 2026, increased by 72% to $4.9 million from $2.9 million in the prior year.
• Total operating expenses for the six months ended June 30, 2026, increased by 74% to $9.9 million from $5.7 million in the prior year.
• The company recorded a significant loss on debt extinguishment and modification of $8.3 million in the three and six months ended June 30, 2026, related to the modification of the Lynrock Lake Term Loan.
• The company has an accumulated deficit of $67.5 million as of June 30, 2026, highlighting its history of losses.
• The company continues to rely on capital raises and may need to raise additional capital, which could lead to significant dilution for existing stockholders.

Risks

• The company may never achieve profitability and will need to continue to raise additional capital.
• The ongoing armed conflicts and geopolitical tensions in the Middle East could disrupt the ability to ship products to distributors in Saudi Arabia and the UAE, materially impacting business, financial condition, results of operations, and liquidity.
• The medical imaging industry is highly competitive, and the company's technology, products, services, or business models may not achieve widespread market acceptance.
• The company's ability to generate revenue from operations and achieve profitability depends on completing development and commercialization of its QT Breast Scanner and future products, manufacturing at commercial scale, and achieving market acceptance.
• Future sales of common stock by the company or existing stockholders could cause the market price of the common stock to decline.
• The company's warrants accounted for as liabilities and changes in their fair value can adversely affect the market price of the common stock.
• The company may not be able to obtain adequate financing or financing on acceptable terms, which could limit its ability to grow or respond to business challenges.

Future Outlook

The company believes its current cash position, along with proceeds from recent financing activities and expected revenue from sales efforts and distribution agreements, will be sufficient to fund its operating plan for at least the next 12 months. However, future capital requirements are uncertain and depend on growth, R&D spending, and inventory needs. Additional financing may be required, potentially leading to dilution or restrictive covenants.

Management Comments

• The company's strategy is predicated on the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease, and that it should be safe, affordable, accessible, and centered on the patients experience.
• We believe that the additional cash received from the Lynrock Lake Term Loan, the extension of the maturity date of the Lynrock Lake Term Loan to March 2029, the additional cash received from the PIPE Investments and the May 2026 Public Offering, and the expected revenue from our direct sales efforts in the U.S., MOQs per the Amended NXC Distribution Agreement, and direct sales efforts and sales through distributors such as Gulf Medical and Al Nagjhi internationally will be sufficient to fund our current operating plan for at least the next 12 months.
• We expect to continue to incur losses, and our ability to achieve and sustain profitability will depend on the achievement of sufficient revenue to support our cost structure. We may never achieve profitability and, unless and until we do, we will need to continue to raise additional capital.

Industry Context

StockSavvy.ai notes that QT Imaging operates in the competitive medical device market, specifically focusing on innovative body imaging systems. The company's reliance on distribution agreements for international expansion, as seen with NXC Imaging, Gulf Medical Co., and Al Naghi Medical Co., is a common strategy in this sector. However, the increasing operating expenses and net losses, despite revenue growth, highlight the challenges of scaling a medical device company and achieving profitability in a market with long development cycles and significant regulatory hurdles.

Comparison to Industry Standards

• The company's revenue growth of over 100% year-over-year in Q2 2026 is strong, but it is crucial to compare this against industry benchmarks for medical imaging device manufacturers, which can vary significantly based on product stage and market penetration.
• The significant increase in operating expenses (R&D and SG&A) is a common trend for medical device companies in their growth phase, as they invest in product development, clinical trials, and market expansion. However, the ratio of these expenses to revenue needs to be monitored against industry peers.
• The company's net loss and accumulated deficit are substantial. While many early-stage medical device companies experience losses, the ability to reach profitability within a reasonable timeframe is a key differentiator. Benchmarking against companies at similar stages of commercialization is essential.
• The company's reliance on multiple financing rounds (PIPEs, public offerings, debt) is typical for capital-intensive medical device development. The terms of these financings, including dilution and debt covenants, should be compared to industry norms.

Legal Proceedings

• Management is not aware of any pending claims that will have a material impact on the unaudited condensed consolidated financial statements as of the date of issuance.

Related Party Transactions

• On April 24, 2025, the company completed the April 2025 Private Placement for net proceeds of $0.5 million from Dr. Avi Katz (Chairman) and Dr. Raluca Dinu (CEO), issuing shares and warrants.
• On January 22, 2026, the company completed the January 2026 Private Placement for gross proceeds of approximately $0.2 million from Dr. Avi Katz, issuing shares and warrants.
• The company has outstanding convertible notes payable to three stockholders totaling $3.2 million in principal, with accrued interest of $0.8 million as of June 30, 2026.
• A working capital note issued to a stockholder is outstanding in the aggregate principal amount of $0.7 million, interest-free, maturing October 1, 2027.
• A sublease agreement with a related party generates $6,000 per month in rental income for the company.

Stakeholder Impact

• Shareholders may experience significant dilution if additional equity financing is pursued.
• Existing shareholders' percentage ownership could decrease with future equity issuances.
• Creditors may face increased risk if the company cannot meet its debt obligations.
• Employees may be impacted by continued losses and the need for potential cost-saving measures.
• Customers and distributors may be affected by potential supply chain disruptions or the company's ability to scale production.

Next Steps

• Continue research, development, and commercialization of innovative body imaging systems.
• Expand market presence through direct sales efforts in the U.S. and international distribution partners.
• Seek expanded regulatory clearances for the Breast Acoustic CT Scanner.
• Build a U.S. sales and marketing team.
• Continue to monitor and manage operating expenses and cash flow.
• Evaluate future capital requirements and pursue additional financing as needed.

Key Dates

Recommendation

While revenue growth is positive, the significant increase in net losses, rising operating expenses, and substantial debt extinguishment loss outweigh the positives. The company's continued reliance on capital raises and the ongoing geopolitical risks in key distribution regions warrant a cautious approach. A 'hold' recommendation reflects the potential for future growth if operational efficiencies are achieved and profitability is demonstrated, but also acknowledges the significant risks and uncertainties.

Keywords

QT Imaging, Breast Acoustic CT Scanner, Medical Device, Revenue Growth, Net Loss, Operating Expenses, Capital Raise, Distribution Agreements